Last reviewed · How we verify
anti-infective therapy levofloxacin
Levofloxacin, an anti-infective therapy, is currently marketed by Shanghai Pulmonary Hospital in China. The key composition patent for levofloxacin is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | anti-infective therapy levofloxacin |
|---|---|
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1, PHASE2)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Effect of Topical Sinonasal Antibiotics (PHASE2)
- Pain and Microbial Reduction of Antimicrobial Corticosteroid Mixture Versus Cryotherapy in Necrotic Teeth (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: